Jitendar Reddy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11080181/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of Imidazo[1,2- <i>a</i>]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. Journal of Medicinal Chemistry, 2017, 60, 1379-1399.	2.9	92
2	Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway. MedChemComm, 2016, 7, 1022-1032.	3.5	22
3	Whole cell screen based identification of spiropiperidines with potent antitubercular properties. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3234-3245.	1.0	31
4	Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nature Communications, 2015, 6, 6715.	5.8	55
5	Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. Tuberculosis, 2014, 94, 282-286.	0.8	22
6	1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5325-5331.	1.4	90
7	<i>N</i> -Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds. Journal of Medicinal Chemistry, 2014, 57, 6642-6652.	2.9	37
8	Benzimidazoles: Novel Mycobacterial Gyrase Inhibitors from Scaffold Morphing. ACS Medicinal Chemistry Letters, 2014, 5, 820-825.	1.3	42
9	4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. Journal of Medicinal Chemistry, 2014, 57, 5419-5434.	2.9	97
10	Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against <i>Mycobacterium tuberculosis</i> . Journal of Medicinal Chemistry, 2014, 57, 4889-4905.	2.9	62
11	Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents. Journal of Medicinal Chemistry, 2014, 57, 5728-5737.	2.9	69
12	Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B. Journal of Medicinal Chemistry, 2013, 56, 8834-8848.	2.9	55
13	Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i> . Journal of Medicinal Chemistry, 2013, 56, 9701-9708.	2.9	140
14	<i>In Vitro</i> and <i>In Vivo</i> Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2506-2510.	1.4	65
15	Effect of repeated dosing on rifampin exposure in BALB/c mice. European Journal of Pharmaceutical Sciences, 2013, 49, 33-38.	1.9	18
16	Effect of Coadministration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 3054-3057.	1.4	25
17	Fast mouse PK (Fast PK): A rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery. European Journal of Pharmaceutical Sciences, 2012, 47, 444-450.	1.9	7